Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook
Inspire Medical Systems (NYSE: INSP) reported strong Q4 2024 financial results with revenue reaching $239.7 million, up 25% year-over-year, and full-year revenue of $802.8 million, a 28% increase from 2023. The company achieved a gross margin of 85.0% in Q4 2024 and reported net income of $35.2 million with diluted EPS of $1.15.
Key operational highlights include the activation of 72 new U.S. centers, bringing the total to 1,435 medical centers, and the creation of 12 new sales territories, totaling 335 in the U.S. Operating cash flow for 2024 reached $130.2 million. The company initiated a $75 million accelerated share repurchase program and surpassed 90,000 patients treated with Inspire therapy.
For 2025, Inspire reaffirms revenue guidance of $940-955 million (17-19% growth) and introduces diluted EPS guidance of $2.10-2.20.
Inspire Medical Systems (NYSE: INSP) ha riportato forti risultati finanziari per il quarto trimestre del 2024, con un fatturato di 239,7 milioni di dollari, in aumento del 25% rispetto all'anno precedente, e un fatturato annuo di 802,8 milioni di dollari, con un incremento del 28% rispetto al 2023. L'azienda ha raggiunto un margine lordo dell'85,0% nel quarto trimestre del 2024 e ha riportato un reddito netto di 35,2 milioni di dollari con un utile per azione diluito di 1,15 dollari.
Tra i principali risultati operativi si segnalano l'attivazione di 72 nuovi centri negli Stati Uniti, portando il totale a 1.435 centri medici, e la creazione di 12 nuovi territori di vendita, per un totale di 335 negli Stati Uniti. Il flusso di cassa operativo per il 2024 ha raggiunto i 130,2 milioni di dollari. L'azienda ha avviato un programma di riacquisto accelerato di azioni da 75 milioni di dollari e ha superato i 90.000 pazienti trattati con la terapia Inspire.
Per il 2025, Inspire conferma le previsioni di fatturato di 940-955 milioni di dollari (crescita del 17-19%) e introduce le previsioni per l'utile per azione diluito di 2,10-2,20 dollari.
Inspire Medical Systems (NYSE: INSP) reportó resultados financieros sólidos para el cuarto trimestre de 2024, con ingresos que alcanzaron 239.7 millones de dólares, un aumento del 25% en comparación con el año anterior, y ingresos anuales de 802.8 millones de dólares, un incremento del 28% respecto a 2023. La compañía logró un margen bruto del 85.0% en el cuarto trimestre de 2024 y reportó un ingreso neto de 35.2 millones de dólares con una utilidad por acción diluida de 1.15 dólares.
Los aspectos operativos clave incluyen la activación de 72 nuevos centros en los Estados Unidos, llevando el total a 1,435 centros médicos, y la creación de 12 nuevos territorios de ventas, sumando un total de 335 en los Estados Unidos. El flujo de caja operativo para 2024 alcanzó los 130.2 millones de dólares. La empresa inició un programa de recompra acelerada de acciones por 75 millones de dólares y superó los 90,000 pacientes tratados con la terapia Inspire.
Para 2025, Inspire reafirma la guía de ingresos de 940-955 millones de dólares (crecimiento del 17-19%) e introduce la guía de utilidad por acción diluida de 2.10-2.20 dólares.
인스파이어 의료 시스템 (NYSE: INSP)은 2024년 4분기 재무 실적이 강력하게 나타나, 수익이 2억 3천 9백 7십만 달러에 도달하며 전년 대비 25% 증가했으며, 연간 수익은 8억 2천 2백만 달러로 2023년 대비 28% 증가했다고 보고했습니다. 이 회사는 2024년 4분기에 85.0%의 매출 총 이익률을 달성하였고, 3천 5백 2십만 달러의 순 이익과 1.15달러의 희석 주당 순이익을 보고했습니다.
주요 운영 하이라이트로는 미국에 72개의 새로운 센터를 활성화하여 총 1,435개의 의료 센터를 만들었으며, 12개의 새로운 판매 영토를 창출하여 미국에서 총 335개로 증가했습니다. 2024년 운영 현금 흐름은 1억 3천 2백만 달러에 도달했습니다. 이 회사는 7천 5백만 달러 규모의 가속화된 자사주 매입 프로그램을 시작했으며, Inspire 요법으로 치료한 환자가 90,000명을 초과했습니다.
2025년을 위해, 인스파이어는 940-955 백만 달러의 수익 가이드를 재확인하고 (17-19% 성장) 2.10-2.20달러의 희석 주당 순이익 가이드를 도입합니다.
Inspire Medical Systems (NYSE: INSP) a annoncé de solides résultats financiers pour le quatrième trimestre 2024, avec des revenus atteignant 239,7 millions de dollars, en hausse de 25% par rapport à l'année précédente, et des revenus annuels de 802,8 millions de dollars, soit une augmentation de 28% par rapport à 2023. L'entreprise a réalisé une marge brute de 85,0% au quatrième trimestre 2024 et a annoncé un bénéfice net de 35,2 millions de dollars avec un bénéfice par action dilué de 1,15 dollar.
Les faits saillants opérationnels incluent l'activation de 72 nouveaux centres aux États-Unis, portant le total à 1.435 centres médicaux, et la création de 12 nouveaux territoires de vente, totalisant 335 aux États-Unis. Le flux de trésorerie d'exploitation pour 2024 a atteint 130,2 millions de dollars. L'entreprise a lancé un programme de rachat d'actions accéléré de 75 millions de dollars et a dépassé les 90.000 patients traités avec la thérapie Inspire.
Pour 2025, Inspire confirme l'estimation des revenus de 940 à 955 millions de dollars (croissance de 17 à 19%) et introduit une estimation du bénéfice par action dilué de 2,10 à 2,20 dollars.
Inspire Medical Systems (NYSE: INSP) berichtete starke Finanzzahlen für das vierte Quartal 2024, mit einem Umsatz von 239,7 Millionen Dollar, was einem Anstieg von 25% im Vergleich zum Vorjahr entspricht, und einem Jahresumsatz von 802,8 Millionen Dollar, was einem Anstieg von 28% im Vergleich zu 2023 entspricht. Das Unternehmen erzielte im vierten Quartal 2024 eine Bruttomarge von 85,0% und meldete einen Nettoerlös von 35,2 Millionen Dollar mit einem verwässerten Gewinn je Aktie von 1,15 Dollar.
Wichtige operative Höhepunkte sind die Aktivierung von 72 neuen Zentren in den USA, womit die Gesamtzahl auf 1.435 medizinische Zentren ansteigt, sowie die Schaffung von 12 neuen Verkaufsgebieten, die insgesamt 335 in den USA ausmachen. Der operative Cashflow für 2024 belief sich auf 130,2 Millionen Dollar. Das Unternehmen startete ein beschleunigtes Aktienrückkaufprogramm im Umfang von 75 Millionen Dollar und übertraf die Zahl von 90.000 Patienten, die mit der Inspire-Therapie behandelt wurden.
Für 2025 bestätigt Inspire die Umsatzprognose von 940-955 Millionen Dollar (17-19% Wachstum) und führt eine Prognose für den verwässerten Gewinn je Aktie von 2,10-2,20 Dollar ein.
- Revenue grew 25% YoY to $239.7M in Q4 2024
- Full year revenue increased 28% to $802.8M
- Q4 net income rose to $35.2M from $14.8M YoY
- Strong gross margin of 85.0% in Q4 2024
- Operating cash flow reached $130.2M in 2024
- Diluted EPS grew 135% YoY to $1.15 in Q4
- Cash position increased to $516.5M from $469.5M YoY
- Operating expenses increased 11% YoY to $171.8M in Q4
- Projected revenue growth for 2025 (17-19%) shows deceleration from 2024's 28%
Insights
Inspire Medical Systems has demonstrated remarkable financial execution in Q4 2024, with multiple indicators suggesting a robust growth trajectory and improving operational leverage. The
Several key metrics deserve attention:
- The activation of 72 new U.S. centers, bringing the total to 1,435, indicates continued market penetration and healthcare provider adoption
- International revenue surge of
163% YoY demonstrates successful market expansion beyond the U.S. - Operating cash flow of
$130.2 million for 2024 reflects strong cash generation capabilities - The healthy cash position of
$516.5 million provides ample runway for growth initiatives
The 2025 guidance of
The company's success in treating over 90,000 patients with Inspire therapy, combined with expanding sales territories and the upcoming Inspire V launch, positions it well for sustained growth in the sleep apnea market. The strategic focus on profitability while maintaining robust growth demonstrates mature financial management and strong market execution.
Inspire Reports Year-over-Year Revenue Growth of
MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024.
Recent Business Highlights and Full Year 2025 Guidance
- Generated revenue of
$239.7 million for the fourth quarter of 2024, a25% increase over the same quarter last year, and revenue of$802.8 million for full year 2024, a28% increase over full year 2023 - Achieved gross margin of
85.0% for the fourth quarter of 2024 - Reported net income of
$35.2 million and diluted net income per share of$1.15 for the fourth quarter of 2024 and net income of$53.5 million and diluted net income per share of$1.75 for full year 2024 - Activated 72 new U.S. centers for the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers providing Inspire therapy
- Created 12 new U.S. sales territories for the fourth quarter of 2024, bringing the total to 335 U.S. sales territories
- Generated
$69.2 million in operating cash for the fourth quarter of 2024, bringing full year 2024 operating cash flow to$130.2 million - Reaffirms full year 2025 revenue to be in the range of
$940 million to$955 million , which would represent year-over-year growth of approximately17% to19% - Introduces full year diluted net income per share guidance of
$2.10 t o$2.20
"We are thrilled with our strong performance in the fourth quarter, growing revenue
Fourth Quarter 2024 Financial Results
Revenue was
Gross margin was
Operating expenses increased to
Operating income was
Net income was
Full Year 2024 Financial Results
Revenue was
Gross margin was
Operating expenses were
Operating income was
Net income was
As of December 31, 2024, cash, cash equivalents, and investments increased to
Full Year 2025 Guidance
Inspire’s previously announced full year 2025 revenue guidance remains between
Gross margin for the full year is anticipated to be in the range of
Inspire is introducing full year 2025 diluted earnings per share guidance of
Webcast and Conference Call
Inspire’s management will host a conference call after market close today, Monday, February 10, 2025, at 5:00 p.m. Eastern Time to discuss these results and answer questions.
To access the conference call, please preregister on
https://register.vevent.com/register/BI7cf46340089b42e6982e8a18b19d4126. Registrants will receive confirmation with dial-in details.
A live webcast of the event can be accessed on https://edge.media-server.com/mmc/p/kjccafzz/. A replay of the webcast will be available on https://investors.inspiresleep.com starting approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measures of Adjusted EBITDA and Adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).
We define Adjusted EBITDA as net income or loss, less interest income, plus interest expense, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense. Net income is the most directly comparable GAAP financial measure to Adjusted EBITDA. We define Adjusted EBITDA margin in this release as Adjusted EBITDA divided by revenue. Net income margin is the most directly comparable GAAP measure to Adjusted EBITDA margin. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.
These non-GAAP financial measures are presented because we believe they are useful indicators of our operating performance. Management uses these measures principally as measures of our operating performance and for planning purposes, including the preparation of our annual operating plan and financial projections. We believe these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe these non-GAAP financial measures are useful to our management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered as an alternative to, or superior to, the most directly comparable GAAP financial measures, as measures of financial performance or cash flows from operations, as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our GAAP results in addition to using non-GAAP financial measures on a supplemental basis. Our definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding our expectations regarding full year 2025 financial outlook and our strategy and investments to grow and scale our business, including our new organizational structure. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our history of operating losses and dependency on our Inspire system for revenues; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies, technologies and pharmaceuticals in our industry; our involvement in current or future legal disputes or regulatory proceedings; our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire system; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; our ability to address quality issues that may arise with our Inspire system; our ability to successfully integrate any acquired business, products, or technologies; changes in global macroeconomic trends; challenges experienced by patients in obtaining prior authorization, our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; our business model and strategic plans for our products, technologies and business, including our implementation thereof; the impact of glucagon-like peptide 1 class of drugs on demand for our Inspire therapy; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and as will be further updated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor & Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
| Inspire Medical Systems, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 239,718 | $ | 192,508 | $ | 802,804 | $ | 624,799 | ||||||||
| Cost of goods sold | 35,988 | 28,054 | 122,986 | 96,576 | ||||||||||||
| Gross profit | 203,730 | 164,454 | 679,818 | 528,223 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 30,336 | 31,052 | 114,128 | 116,536 | ||||||||||||
| Selling, general and administrative | 141,510 | 124,105 | 529,607 | 451,958 | ||||||||||||
| Total operating expenses | 171,846 | 155,157 | 643,735 | 568,494 | ||||||||||||
| Operating income (loss) | 31,884 | 9,297 | 36,083 | (40,271 | ) | |||||||||||
| Other (income) expense: | ||||||||||||||||
| Interest and dividend income | (5,552 | ) | (5,870 | ) | (23,247 | ) | (20,560 | ) | ||||||||
| Interest expense | 22 | — | 22 | — | ||||||||||||
| Other expense (income), net | 778 | (73 | ) | 855 | 195 | |||||||||||
| Total other income | (4,752 | ) | (5,943 | ) | (22,370 | ) | (20,365 | ) | ||||||||
| Income (loss) before income taxes | 36,636 | 15,240 | 58,453 | (19,906 | ) | |||||||||||
| Income taxes | 1,412 | 477 | 4,944 | 1,247 | ||||||||||||
| Net income (loss) | 35,224 | 14,763 | 53,509 | (21,153 | ) | |||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation (loss) gain | (151 | ) | 144 | (65 | ) | 140 | ||||||||||
| Unrealized (loss) gain on investments | (1,013 | ) | 612 | (199 | ) | 746 | ||||||||||
| Total comprehensive income (loss) | $ | 34,060 | $ | 15,519 | $ | 53,245 | $ | (20,267 | ) | |||||||
| Basic income (loss) per share | $ | 1.18 | $ | 0.50 | $ | 1.80 | $ | (0.72 | ) | |||||||
| Diluted income (loss) per share | $ | 1.15 | $ | 0.49 | $ | 1.75 | $ | (0.72 | ) | |||||||
| Basic weighted average shares outstanding | 29,827,947 | 29,517,375 | 29,763,395 | 29,302,154 | ||||||||||||
| Diluted weighted average shares outstanding | 30,751,338 | 30,236,821 | 30,543,274 | 29,302,154 | ||||||||||||
| Inspire Medical Systems, Inc. Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts) | |||||||
| December 31, | |||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 150,150 | $ | 185,537 | |||
| Investments, short-term | 295,396 | 274,838 | |||||
| Accounts receivable, net of allowance for credit losses of | 93,068 | 89,884 | |||||
| Inventories, net | 80,118 | 33,885 | |||||
| Prepaid expenses and other current assets | 12,074 | 9,595 | |||||
| Total current assets | 630,806 | 593,739 | |||||
| Investments, long-term | 70,995 | 9,143 | |||||
| Property and equipment, net | 71,925 | 39,984 | |||||
| Operating lease right-of-use assets | 23,314 | 22,667 | |||||
| Other non-current assets | 11,343 | 11,278 | |||||
| Total assets | $ | 808,383 | $ | 676,811 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 38,687 | $ | 38,839 | |||
| Accrued expenses | 49,814 | 39,266 | |||||
| Total current liabilities | 88,501 | 78,105 | |||||
| Operating lease liabilities, non-current portion | 30,039 | 24,846 | |||||
| Other non-current liabilities | 148 | 1,346 | |||||
| Total liabilities | 118,688 | 104,297 | |||||
| Stockholders' equity | |||||||
| Preferred Stock, | — | — | |||||
| Common Stock, | 30 | 30 | |||||
| Additional paid-in capital | 981,043 | 917,107 | |||||
| Accumulated other comprehensive income | 536 | 800 | |||||
| Accumulated deficit | (291,914 | ) | (345,423 | ) | |||
| Total stockholders' equity | 689,695 | 572,514 | |||||
| Total liabilities and stockholders' equity | $ | 808,383 | $ | 676,811 | |||
| Inspire Medical Systems, Inc. Reconciliation of Non-GAAP Financial Measures (unaudited) (in thousands) | ||||||||||||||||
| Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net income (loss) | $ | 35,224 | $ | 14,763 | $ | 53,509 | $ | (21,153 | ) | |||||||
| Interest and dividend income | (5,552 | ) | (5,870 | ) | (23,247 | ) | (20,560 | ) | ||||||||
| Interest expense | 22 | — | 22 | — | ||||||||||||
| Income taxes | 1,412 | 477 | 4,944 | 1,247 | ||||||||||||
| Depreciation and amortization | 2,478 | 816 | 6,550 | 2,846 | ||||||||||||
| EBITDA | 33,584 | 10,186 | 41,778 | (37,620 | ) | |||||||||||
| Stock-based compensation expense | 29,140 | 22,849 | 116,007 | 82,470 | ||||||||||||
| Adjusted EBITDA | $ | 62,724 | $ | 33,035 | $ | 157,785 | $ | 44,850 | ||||||||
| Reconciliation of GAAP Net Income Margin and Non-GAAP Adjusted EBITDA Margin | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net income margin(1) | 15 | % | 8 | % | 7 | % | (3 | ) | % | |||||||
| Interest and dividend income | (2 | ) | % | (3 | ) | % | (3 | ) | % | (3 | ) | % | ||||
| Interest expense | — | % | — | % | — | % | — | % | ||||||||
| Income taxes | — | % | — | % | 1 | % | — | % | ||||||||
| Depreciation and amortization | 1 | % | — | % | 1 | % | — | % | ||||||||
| Stock-based compensation expense | 12 | % | 12 | % | 14 | % | 13 | % | ||||||||
| Adjusted EBITDA margin(2) | 26 | % | 17 | % | 20 | % | 7 | % | ||||||||
(1) Net income margin is calculated as net income (loss) divided by total revenue.
(2) Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total revenue.
FAQ
What was Inspire Medical Systems' (INSP) revenue growth in Q4 2024?
How much did INSP's earnings per share grow in Q4 2024?
What is Inspire Medical Systems' revenue guidance for 2025?
How many U.S. medical centers now provide Inspire therapy as of Q4 2024?
What is INSP's projected earnings per share guidance for 2025?
